The global cell and gene therapy (CGT) industry is poised for remarkable growth, driven by significant advances in life ...

So, researchers are working to create more medicines, such as those made from messenger RNA (mRNA), that can be sprayed and ...

"Dr. Mora's vision for advancing novel therapeutic platforms will be invaluable ... Previously, Dr. Mora was Vice President of Immunoengineering at Moderna, where he applied LNP-mRNA technology to ...

These targets include PNPLA3 where we are using an mRNA ... we are advancing WVE-007, our GalNAc-siRNA targeted inhibit E ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Good afternoon and welcome everyone to the GeoVax Third Quarter 2024 Corporate Update Call. My name is Michelle and I will facilitate today ...

A groundbreaking study introduces stable inhalable mRNA treatment using nanoparticles that hold up during nebulization, ...

CureVac NV (CVAC) reports robust revenue growth and strategic advancements in oncology, despite ongoing litigation challenges.

Commenting on the quarter Dr. Alexander Zehnder, Chief Executive Officer of CureVac (CVAC) said: “The third quarter was truly ...

Brad Miller, Moderna's CIO, has driven technology innovation to help drive continued gains for the roughly $7 billion revenue ...

The clinical study is funded by Biomedical Advanced Research and Development Authority (BARDA ... and clearance to proceed into the clinic with our STARR® self-amplifying mRNA technology is a key step ...

The Middle East Veterinary Vaccine Market is poised for steady growth, with a projected market size of USD 627.1 million in 2023. The market is expected to expand at a CAGR of 4% through 2033, ...